Gursoy P - Search Results

1

Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.

Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Surmeli Z, et al. Among authors: gursoy p. Tumour Biol. 2016 Mar;37(3):3665-73. doi: 10.1007/s13277-015-3265-x. Epub 2015 Oct 13. Tumour Biol. 2016. PMID: 26462835

2

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Gursoy P, et al. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875. doi: 10.1007/s00432-022-03984-5. Epub 2022 Apr 5. J Cancer Res Clin Oncol. 2023. PMID: 35381885

3

Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.

Ekinci F, Balcik OY, Demir B, Gursoy P, Ozveren A, Erdogan AP. Ekinci F, et al. Among authors: gursoy p. J Coll Physicians Surg Pak. 2022 Aug;32(8):996-1003. doi: 10.29271/jcpsp.2022.08.996. J Coll Physicians Surg Pak. 2022. PMID: 35932122

4

Savaş P, Serin G, Gürsoy P, Zekioğlu O, Özdemir N. Savaş P, et al. Among authors: gursoy p. Pol J Pathol. 2023;74(2):65-74. doi: 10.5114/pjp.2023.129014. Pol J Pathol. 2023. PMID: 37728465 Free article.

5

Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.

Sozer Karadagli S, Gursoy P. Sozer Karadagli S, et al. Among authors: gursoy p. J Oncol Pharm Pract. 2024 Mar;30(2):404-407. doi: 10.1177/10781552231208390. Epub 2023 Oct 30. J Oncol Pharm Pract. 2024. PMID: 37899576

6

Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients: A single-institution retrospective analysis.

Gürsoy P, Çakar B, Nart D, Göker E. Gürsoy P, et al. Indian J Cancer. 2022 Apr-Jun;59(2):251-256. doi: 10.4103/ijc.IJC_71_20. Indian J Cancer. 2022. PMID: 35017371 Free article.

7

The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.

Gürsoy P, Çakar B, Almuradova E, Karateke M, Doğanavşargil B, Sezak M, Harman M, Karabulut B. Gürsoy P, et al. J Chemother. 2021 May;33(3):180-186. doi: 10.1080/1120009X.2020.1861531. Epub 2020 Dec 21. J Chemother. 2021. PMID: 33349195

8

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.

Gursoy P, Çakar B, Gunenc D, Nart D, Çınkooğlu A, Katgı N. Gursoy P, et al. Turk Thorac J. 2022 Jan;23(1):45-51. doi: 10.5152/TurkThoracJ.2021.21151. Turk Thorac J. 2022. PMID: 35110200 Free PMC article.

9

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: gursoy p. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239

10

Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience.

Gürsoy P, Çakar B, Ön S, Göker E, Nart D. Gürsoy P, et al. Turk Thorac J. 2022 Jul;23(4):290-295. doi: 10.5152/TurkThoracJ.2022.21270. Turk Thorac J. 2022. PMID: 35848437 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page